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COPPER-CYSTEAMINE AND METHODS OF
USE
CROSS REFERENCE TO RELATED
APPLICATIONS
This application is a National Stage Entry of International
Application No. PCT/US14/48557 filed Jul. 29, 2014, which
claims the benefit of Provisional Application Serial Number
61/859,460, filed on Jul. 29, 2013, and Provisional Appli-
cation Serial Number 61/932,112, filed Jan. 27, 2014, the
entire disclosure of which are incorporated herein by refer-
ence in their entirety.
FIELD OF THE INVENTION
A novel copper-cysteamine (Cu-Cy) complex and its
properties are disclosed. Further disclosed are compositions
and materials which comprise the Cu-Cy complex. Yet
further disclosed are methods of using the Cu-Cy complex,
inter alia, as a treatment of cancer and as a means for
detecting sources of radiation. Still further disclosed are
methods for preparing various morphologiesofthe disclosed
Cu-Cy complex.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawingsillustrate by way of example and
not limitation. For the sake of brevity and clarity, every
feature of a given structure is not always labeled in every
figure in which that structure appears.
FIGS. 1A-1F depict the SEM (FIG.1A, FIG.1B, and FIG.
1C) and HRTEM (FIG. 1D, FIG. 1E, and FIG. 1F) images
of the disclosed Cu-Cycrystals. The inset in FIG. 1D is the
electron diffraction pattern of the crystals.
FIGS. 2A-2E depict SEM images (FIG. 2A, FIG. 2B, and
FIG. 2C) of the disclosed Cu-Cy crystals obtained without
stirring. High resolution SEM Images (FIG. 2D) and (FIG.
2E) show the edge area of the large crystal in the image
(FIG. 2C).
FIG. 3 depicts the XRD pattern of Cu-Cycrystals of the
invention.
FIG.4 depicts the photoluminescence emission spectra on
the right of Cu-Cy crystals after excitation at 360 nm.
Excitation spectra are shown on the left. The 607 nm
emission has the solid line excitation and the 633 nm
emission has the excitation spectrum represented by the
dashedline.
FIG. 5 depicts the lifetime spectrum of Cu-Cy crystals. A
straightline is plotted as a comparison to show thatthe close
linear property of the decay curve portion after 2 ps.
FIG. 6 depicts the X-ray luminescence spectrum of the
Cu-Cy crystals of the invention.
FIG. 7 depicts the XPS profile of Cu-Cy crystals of the
invention. The peaks are assigned as follows—peak A
Cu@p), peak B Cu@s), peak C S(2p), peak D Cl(2p), peak
E Sp), peak F Cl(1s), peak G Ag(3d), peak H N(1s), peak
I Ods), peak J Ag(3p3/2), peak K Ag(3p1/2), peak L
Cu(Auger), peak M Ag(3s), peak N Cu(2p3/2), peak O
Cu(2p1/2) and peak P O(Auger).
FIG. 8 depicts Quantum yield measurementof the dis-
closed Cu-Cy crystals in water by using Rhodamine B as a
standard (I). The straight line is the linear fitting for
Rhodamine B while the linearfitting for the Cu-Cy in water
is almost entirely coincidental with the depicted values (¥).
FIG. 9 depicts the viabilities of MCF-7 cells at different
concentrations of the disclosed Cu-Cycrystals.
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FIGS. 10A-10D depict the images of MCF-7 cells incu-
bated for 24 hours with the disclosed Cu-Cy crystals. The
cells were stained with 4',6-diamidino-2-phenylindole
(DAPI). FIG. 10A: Bright-field image, FIG. 10B: Fluores-
cence image excited by 405 nm, FIG. 10C: Fluorescence
image excited by 360 nm,FIG. 10D: a photo combination of
FIG. 10B and FIG. 10C. The scale bar is always 50 um.
FIGS. 11A-11D depict the comparison of UV light (350
nm) destruction on humanhepatocellular liver cells (HEPT)
without(top row, FIG. 11A and FIG. 11B) and with (bottom
row, FIG. 11C and FIG. 11D) Cu-Cycrystals. Significant
cell death is only observed in the case of Cu-Cycrystals and
UV irradiation. The scale bar is always 100 um.
FIGS. 12A-12D depict the comparison of UV light (350
nm) destruction on human breast cancer (MCF-7) cells
without(top row, FIG. 12A and FIG. 12B) and with (bottom
row, FIG. 12C and FIG. 12D) Cu-Cycrystals. Significant
cell death is only observed in the case of Cu-Cycrystals and
UV irradiation. The scale bar is always 100 um.
FIGS. 13A-13D depict the comparison of X-ray (2 Gy)
destruction on human breast cancer (MCF-7) cells without
(top row, FIG. 14A and FIG. 14B) and with (bottom row,
FIG. 14C and FIG. 14D) Cu-Cycrystals. Significant cell
death has been observed in the presence of Cu-Cycrystals
and X-ray irradiation. The scale bar is always 100 um.
FIGS. 14A-14D depict the comparison of X-ray (2 Gy)
destruction on human prostate cancer (PC3) cells without
(top row, FIG. 14A and FIG. 14B) and with (bottom row,
FIG. 14C and FIG. 14D) Cu-Cycrystals. Significant cell
death is only observed in the case of Cu-Cy crystals and
X-ray irradiation. The scale bar is always 100 pm.
FIG. 15 depicts the cell (PC-3) viabilities in the presence
of (a) Cu-Cy crystals, (b) UV light treated Cu-Cy crystals,
and (c) X-ray treated Cu-Cy crystals at two concentrations
respectively.
FIG. 16 depicts X-ray luminescence of disclosed Cu-Cy
invention versus CdTe quantum dots. Both measurements
are taken in water at a concentration of 0.02M.
FIG. 17 depicts X-ray luminescenceofpolyvinyl toluene/
2,5-diphenyloxazole (PVT/PPO) polymer and Cu-Cy/PVT/
PPO composites. The volume of Cu-Cy in PVT is only 1%.
FIGS. 18A & 18B depicts singlet oxygen production in
PPIX (A), ZnO (@), and the disclosed Cu-Cy(¥) versus
control (Ml) when excited by X-rays (FIG. 18A); and singlet
oxygen production in PPIX (@) and Cu-Cy (A) versus
control (Ml) using UV light (365 nm) (FIG. 18B).
FIG. 19 depicts single crystals of the Cu-Cy of the
invention, with size of about 60 umx60 umx450 um. On the
left are the crystals emitting red fluorescence excited by a
UV lamp; on the right is one crystal imaged by an optical
microscope(top right) and a microscope fluorescence image
excited at 350 nm (bottom right).
FIG. 20 depicts the structure of a particular crystalline
form of the disclosed complex. Selected distances and
angles are Cu(1)-S(1) 2.3167(9) A; Cu(2)-S(1), 2.2474(8)
A; Cu(2)-Cl(1), 2.2739(12) A.
FIG. 21A depicts the ‘*C CP-MASspectra of the dis-
closed Cu-Cy crystals and FIG. 21B depicts the '*C CP-
MASspectra of cysteamine.
FIG. 22 depicts photoluminescence emission spectrum
(black, 2,,=360 nm) and X-ray luminescence of Cu-Cy.
FIG. 23 shows a comparison of X-ray (2Gy) destruction
of MCF-7 cells using Cu-Cy particles of the invention. The
images show MCF-7 live (green, calcein-AM stain) and
dead (red, EthD-1 stain) cells. The scale bar is 100 um.
US 9,593,131 B2
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FIG. 24 shows time-dependent in vivo images of mice
with different sized MCF-7 tumorsafter treatment at 1, 3, 5,
9 and 13 days.
FIG. 25 pictures the breast tumors collected after MCF-7
tumor-bearing mice were sacrificed on day 13 of treatment.
DETAILED DESCRIPTION
The materials, compounds, compositions, articles, and
methods described herein may be understood more readily
by reference to the following detailed description of specific
aspects of the disclosed subject matter and the Examples
includedtherein.
Before the present materials, compounds, compositions,
and methods are disclosed and described, it is to be under-
stood that the aspects described below are not limited to
specific synthetic methodsor specific reagents, as such may,
of course, vary. It is also to be understood that the termi-
nology used hereinis for the purposeofdescribing particular
aspects only and is not intended to be limiting.
Also, throughout this specification, various publications
are referenced. The disclosures of these publicationsin their
entireties are hereby incorporated by reference into this
application in order to more fully describe the state oftheart
to which the disclosed matter pertains. The references dis-
closed are also individually and specifically incorporated by
reference herein for the material contained in them that is
discussed in the sentence in which the reference is relied
upon.
General Definitions
In this specification and in the claims that follow, refer-
ence will be made to a number of terms, which shall be
defined to have the following meanings:
All percentages, ratios and proportions herein are by
weight, unless otherwise specified. All temperatures are in
degrees Celsius (° C.) unless otherwise specified.
The terms“a” and “an”are defined as one or more unless
this disclosure explicitly requires otherwise.
Ranges may be expressed herein as from “about” one
particular value, and/or to “about” another particular value.
When such a range is expressed, another aspect includes
from the one particular value and/or to the other particular
value. Similarly, when values are expressed as approxima-
tions, by use of the antecedent “about,”it will be understood
that the particular value forms another aspect. It will be
further understood that the endpoints of each of the ranges
are significant both in relation to the other endpoint, and
independently of the other endpoint.
Values expressed as “greater than” do not include the
lower value. For example, when the “variable x” is defined
as “greater than zero” expressed as “O<x”the value of x is
any value, fractional or otherwise that is greater than zero.
Similarly, values expressed as “less than” do not include
the upper value. For example, when the “variable x” is
defined as “less than 2” expressed as “x<2”the value of x is
any value, fractional or otherwise that is less than 2.
“Optional” or “optionally” means that the subsequently
described event or circumstance can or cannot occur, and
that the description includes instances where the event or
circumstance occurs and instances where it does not.
The terms “comprise” (and any form of comprise, such as
“comprises” and “comprising”), “have” (and any form of
have, such as “has” and “having”), “include” (and any form
of include, such as “includes” and “including”) and “con-
tain” (and any form of contain, such as “contains” and
“containing”’) are open-ended linking verbs. As a result, an
29 ccsapparatus that “comprises,” “has,” “includes”or “contains”
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one or more elements possesses those one or more elements,
but is not limited to possessing only those elements. Like-
wise, a methodthat “comprises,” “has,”“includes”or “con-
tains” one or more steps possesses those one or moresteps,
butis not limited to possessing only those one or moresteps.
Any embodimentof any of the apparatuses, systems, and
methods can consistof or consist essentially of—rather than
comprise/include/contain/have—anyof the described steps,
elements, and/or features. Thus, in any of the claims, the
term “consisting of’ or “consisting essentially of’ can be
substituted for any of the open-ended linking verbs recited
above, in order to change the scope of a given claim from
what it would otherwise be using the open-ended linking
verb.
The feature or features of one embodiment may be
applied to other embodiments, even though not described or
illustrated, unless expressly prohibited by this disclosure or
the nature of the embodiments.
Any embodimentof any of the apparatuses, systems, and
methods can consistof or consist essentially of—rather than
comprise/include/contain/have—anyof the described steps,
elements, and/or features. Thus, in any of the claims, the
term “consisting of’ or “consisting essentially of’ can be
substituted for any of the open-ended linking verbs recited
above, in order to change the scope of a given claim from
what it would otherwise be using the open-ended linking
verb.
The feature or features of one embodiment may be
applied to other embodiments, even though not described or
illustrated, unless expressly prohibited by this disclosure or
the nature of the embodiments.
Details associated with the embodiments described above
and others are described below.
COMPOUND
Disclosed herein is a copper-cysteamine (Cu-Cy) having
the formula:
CusCl(SR)>
wherein R is —CH,CH,NH,. The terms “copper-cysteam-
ine,” “Cu-Cy material,” “Cu-Cy complex,” “Cu-Cy,” “dis-
closed material,” “disclosed complex,” “disclosed com-
pound” and the like are used herein interchangeably
throughout the present disclosure to represent the above-
identified chemical compound. As depicted in the appended
Figures, the compound can have various forms depending
upon the method of preparation employed by the formulator.
The present disclosure does not exclude any morphology,
crystalline form andthelike.
The disclosed complex exhibits emission peaks at 607 nm
and 633 nm and X-ray luminescence at 633 nm. The Cu-Cy
materials are stable in aqueous solution, as well as other
common solvents.
The disclosed Cu-Cy materials can be formed in crystals
in micrometer or millimeter size. In addition to the micron-
sized crystals, smaller crystals from tens to several hundred
nanometers have also been prepared. The methods for
producing the copper-complex materials can be accom-
plished without the protection afforded by an inert atmo-
sphere, for example, nitrogen or argon blanketing or the
need for hazardous organic solvents. After simply mixing
and heating the copper and organic reactants in water, the
Cu-Cy crystals are formed and isolated from water solution
as precipitation. The product can be then washed with water
and ethanol as more specifically described in the examples.
US 9,593,131 B2
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Sonication helps cleaning the products but is likely to break
the crystals into small pieces.
EXAMPLE1
Preparation of the Disclosed Cu-Cy Compound
Copper(I]) chloride dihydrate (99.99%), 2-mercaptoeth-
ylamine hydrochloride (Cysteamine hydrochloride or Cys,
98%) and Sodium hydroxide (98%) were purchased from
Sigma (USA). All the chemicals were used as received.
Deionized (DI) water was used as the reaction solvent
without further purification.
CuCl,.2H20 (0.460 g, 2.698 mmol,) was dissolved in DI
water followed by addition of cysteamine (0.636 g, 8.244
mmol). With excessive cysteamine, the Cu?* (Cu(II) was
completely reduced to Cu* (Cu(])), expressed as 2HSR+Cu
(ID=Cu()-SR+/2RSSR+42H"*. After adjusting the pH value
to 8 by adding a 2.5 M NaOHsolution, the solution was
stirred for about 2 hours at room temperature until the
solution turned to deep violet as a result of oxidation.
Without wishing to be limited by theory, an intermediate
product consists of both Cu(I) and Cu(I]) is proposed as the
cause of the violet color and has the proposed formula
CudD),(SR),0Cu(D,(SR),.
The solution wasthen heatedto its boiling temperature for
30 minutes. Crystals of Cu,Cl(SR), were precipitated from
the solution and other reaction products were removed with
the supernatant. The obtained Cu,Cl(SR), crystals were
further centrifuged and washed using a mixture of DI water
and ethanol (v/v=5:4) three times. Finally, the crystals were
dried completely in a vacuum oven at room temperature
overnight. Larger single crystals were obtained for longer
time with no stirring. Without wishing to be limited by
theory, the overall reaction to prepare the desired copper-
cysteamine complex is as follows:
6 CuCl+12HSR+12NaO0H ——™ 2Cu;Cl(SR)>+3RSSR+2Na(SR)+10NaCl+12H,O
wherein R is —CH,CH,NH,.
X-ray Photoelectron Spectroscopy (XPS).
The Cu-Cy crystal powders were dispersed in ethanol and
deposited on the surface of silver coated silicon wafer. After
sample drying in a vacuum oven at 40° C.for a whole night,
the XPS survey and quantification report were then carried
out by using a Perkin-Elmer PHI 560 high performance
spectrometer.
Luminescence Decay Lifetimes
The luminescencelifetimes were collected using a nano-
second optical parametric oscillator/amplifier (Spectra-
Physics MOPO-730) operating at a 10 Hz repetition rate and
tunable between 440 and 1800 nm.The output of the MOPO
system was frequency doubled in a KDPcrystal and directed
onto the particles. Emission wascollected at right angles to
the excitation and focused into a 4% meter monochromator
equipped with a standard photomultiplier tube.
Photoluminescence Measurement.
The photoluminescence spectrum was measured by dis-
persing 0.1 mg Cu-Cy particles into 3 mL DI water and
recorded by a Shimadzu RF-5301PC fluorescence spectro-
photometer (Kyoto, Japan).
X-ray Luminescence Measurement.
The x-ray luminescence spectrum was measured in a
light-proof X-ray cabinet equipped with optic fiber connec-
tion to an outside detector (QE65000 spectrometer, Ocean
Optics Inc., Dunedin, Fla.). The X-ray Irradiation was
performed using a Faxitron RX-650 (Faxitron X-ray Corp,
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IL, USA) at 90 kV with a 12 inch mm source-object distance
and 5 mm distance optic fiber to object, at 135°. The
luminescence spectra were recorded using a QE65000 spec-
trometer (Ocean Optics Inc., Dunedin, Fla.), connected to
the X-ray chamberusing a 0.6 mm core diameter optic fiber
(P600-2-UV-V is, Ocean Optics Inc, Dunedin, Fla.), which
has a probe head extended inside the X-ray chamber and
positioned at 45° and 5 mm away from sample surface.
Quantum Yield (QY) Measurements.
The quantum yield measurement wascarried out by using
10 mm fluorescence cuvettes with Shimadzu UV-2450
UV_vis spectrophotometer and RF-5301PC fluorescence
spectrophotometer. Rhodamine B in water (quantum yield
0.31) was chosen as a standard. For each of Rhodamine B
and Cu-comples water solutions, five different concentra-
tions and their corresponding measured integrated lumines-
cence intensities (A,,=368 nm) were recorded respectively
and plotted in FIG. 9. Then linear fitting was applied (red
lines) for each case and the quantum yield of Cu-Cycrystals
in water was calculated according to: =0.31* SlopeX/
SlopeST, where the subscript “X” and “ST” refer to the
Cu-Cy and Rhodamine Brespectively. In order to minimize
re-absorption effects, absorbencies in the 10 mm fluores-
cence cuvette were always kept under 0.1.
Solid-State NMR Spectropscopy.
'3C CP-MASspectra were acquired on a Varian/Chemag-
netics Infinityplus 9.4 T WB spectrometer and a 21.1 T
Bruker Avance II spectrometer, respectively. All the 1°C
CP-MASspectra were obtained at room temperature with a
contact time of 1 ms and a pulse delay of 5 s. The sample
spinning rates were 8 and 10 kHz for (1) and cysteamine
hydrochloride, respectively. '*C chemical shifts were refer-
enced externally to the resonance ofthe methylene carbon in
adamantane (38.55 ppm relative to TMS)
Single Crystal X-ray Diffraction Analysis.
In order to determine their structure, crystals of the
invention suitable for single crystal X-ray diffraction were
obtained using the seed growth method. A pale brown
rod-like crystal of the invention, (C,H,,Cl,Cu,N.S,), hav-
ing the approximate dimensions of 0.10x0.03x0.03 mm,
coated with oil (Paratone 8277, Exxon), was collected onto
the elongated aperture of a mounted MicroLoop E™ (diam-
eter of the aperture: 100 microns; MiTeGen—Micro-tech-
nologies for Structural Genomics; USA).
The crystal was then mounted onto the goniometer head,
which was quickly transferred to the cold stream of the
Oxford cryo-jet. The mounted MicroLoop™had previously
been attached reusable goniometer bases consisting of stain-
less steel magnetic base and a copperpost extending up from
the stainless steel base. The MicroLoop™ is grabbed and
securely hold in reusable goniometer bases without using
epoxy.
All measurements were made on a Nonius KappaCCD
4-Circle Kappa FR540C diffractometer using monochro-
mated Mo Kradiation (A=0.71073 A) at -100° C. An initial
orientation matrix and cell was determined from 10 frames
using @ scans and the data were measured using w-scans. A
total of 2662 reflections were collected. Cell parameters
were initially retrieved using the COLLECT software,
refined with the HKL DENZO and SCALEPACKsoftware
using 1355 observedreflections with 1.00°<@<30.03° (mo-
saicity:) 0.428(3)° from the data collection, and corre-
sponded to a monoclinic cell. Data reductions were per-
formed with the HKL DENZO and SCALEPACKsoftware,
which corrects for beam inhomogeneity, possible crystal
decay, Lorentz and polarization effects. A multi-scan absorp-
tion correction was applied (SCALEPACK). The crystal
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structures were solved using the heavy atoms method (Pat-
terson) and refined by full-matrix least-squares method on
F? with SHELXL-2012. The non-hydrogen atoms were
refined anisotropically. Hydrogen atoms were included at
geometrically idealized positions and were notrefined. The
isotropic thermal parameters of these hydrogen atoms were
fixed at 1.2 or 1.5 times that of the preceding carbon or
nitrogen atom, respectively. Neutral atom scattering factors
for non-hydrogen atoms and anomalous dispersion coefti-
cients are contained in the SHELXL-2012 program. Further
details for the determination of crystal structures are given
in the supporting information. Molecular thermal ellipsoid
plots were prepared using OLEX-2 for Windows.
The obtained Cu-Cycrystals are depicted in FIGS. 1A-1F
with the use of scanning electron microscopy (SEM,Hitachi
S-5000H system) and transmission electron microscopy
(TEM,Hitachi 9500). The crystals are substantially rectan-
gular shaped andin the sizes ofmicrometers (FIGS. 1A-1B).
Small irregular pieces could be broken from larger crystals.
At a higher magnification (FIG. 1C) agglomeration ofnano-
sized particles can been observed.
The smaller crystals were observed by TEM (FIG.1D).
Their electron diffraction pattern (inset, FIG. 1D) suggests
that these small crystals are single crystals. Further, their
high resolution TEM imagesdisplay clear uniform lattice
fringes (FIGS. 1E-1F). The HRTEM images demonstrate
that these small crystals are highly crystalline and about 70
nm to 200 nm insize.
The microcrystal growth of the disclosed compound can
be controlled by adjusting various factors, for example,
choice of solvent, pH, temperature, etc. The disclosed Cu-
Cy crystals can be obtained in the size of tens of microm-
eters in the absenceofstirring. FIGS. 2A-2E provide supple-
mentary SEM images.
FIG. 3 represents the XRD pattern of the Cu-Cy crystal
powder. The Cu-Cycrystals exhibited very sharp and inten-
sive peaks. The lattice spacing measured from the high
resolution TEM images are d=0.347 nm (FIG. 1E) and
d=0.227 nm (FIG. 1F), which match the d values calculated
from the XRD peaks at 25.70° (d=0.346 nm) and 39.94°
(d=0.226 nm) respectively.
The crystals used for single crystal XRD are shown in
FIG. 19. The crystal size is approximately 60 umx60
umx450 um and the luminescence spectra (FIG. 6) of these
crystals are the same as that of the powder samples. The
crystal structure of Cu-Cy (FIG. 20) was determined by
single crystal X-ray diffraction. The compoundcrystallizes
in the monoclinic space group C2/c and cell parameters are
a=7.5510(4) A, b=16.9848(7) A, c=7.8364(4) A, B=104.798
(3)°. Its empirical formula is Cu,Cl(SR), with formula
weight 378.38 g/mol. The new structure includes two dif-
ferent Cu atoms: Cu(1) and Cu(2), which bind to 4 and 3
other atoms respectively. The valence calculation shows
they are both Cu* ions. In many examples of coordination
structures, a thiolate sulfur atom typically binds less than 4
metal atoms.In the disclosed Cu-Cycrystals, the sulfur atom
bridges 4 Cu atoms simultaneously.
To further probe the oxidation state of Cu in the Cu-Cy,
'3C CP-MASspectra of Cu-Cy and the ligand precursor
(cysteamine hydrochloride) were acquired (FIGS. 21A-
21B). For the ligand precursor (HS-C(1)H,—C(2)H,—
NH,.HCl), the isotropic chemical shifts of carbon atoms
C(1) and C(2) are 24.3 and 43.8 ppm, respectively. Upon
formation of the disclosed compound, these two peaks
shifted to the downfield direction and now appear at 38.0
and 49.4 ppm. The observation that the carbon atom C(1)
exhibits a significantly larger shift is indicative of the copper
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ion bound to the sulfur atom. The facts that the observed
shifts of the ligand precursor are small (less than 15 ppm)
upon coordination and that no spinning side bands were
observed at the relatively low spinning speed used for the
crystals of the invention suggest that the Cu ion is a
diamagnetic species (i.e. Cut). If the Cu oxidation state
were 2+, much larger shifts would be observed due to the
paramagnetic contribution to the isotropic shift, especially
for the carbon atom C(1). Furthermore, a large number of
spinning sidebandsarising from the large paramagnetic shift
anisotropy (PSA) are expected, which are often observed for
the carbon atoms near a paramagnetic center. For example,
in a Cu2+-containing metal-organic framework, HKUST-1,
the resonance of the carboxylate carbon in the benzenetri-
carboxylate ligand exhibits a very large upfield paramag-
netic shift of 256.8 ppm from 170.8 ppm ofthe free ligand
(benzenetricarboxylic acid) to -86 ppm of HKUST-1. The
aromatic carbons, on the other hand, experience paramag-
netic shifts of 98-92 ppm, but to the opposite direction(1.e.,
the shift is downfield) [1, 2]. In addition, at 10 kHz (a
spinning speed comparableto that usedin this study) a larger
numberof intense sidebands were seen resulting from the
PSA. Therefore, the NMR data are consistent with single-
crystal XRD results that the oxidation state of copper in the
crystals of the invention is +1, rather than +2.
The copper-complex material of the invention has less
atoms in its repeating unit cell than the previous reported
Cu-Cy crystals Cu,,Cl,;(SR'), and Cu,Cl,(SR'),, where
R'=CH.,CH,NH;. The structure of the disclosed copper-
complexes is simpler. As seen in FIG. 20, both ends (thiol
group and amine group) from SR bond to Cu(1), the thiol
group forms a covalence bond with Cu(1) while the electron
pair from amine group forms coordinate bond with the same
atom. While in the previous Cu-Cy structures, only thiol
groups bond with Cu atoms. Here, chelation may be respon-
sible for stabilizing the structure.
The disclosed Cu-Cy emitsvisible light when excited by
ultra violet or X-ray electromagnetic radiation,i.e., photolu-
minescence and X-ray luminescence. This luminescenceis
observed over a pH range of from about 5 to about 14. FIG.
4 shows the photoluminescence emission and excitation
spectra of the disclosed Cu-Cy crystals in water. Two red
emissions peaking at 607 nm and 633 nm are observed from
the Cu-Cy crystals in water, which indicates two lumines-
cence emitting centers.
The lifetime spectrum of Cu-Cy particles was plotted in a
log(intensity)—1time format as shown in FIG. 5. The decay
curve show a non-linear property in the logarithmic scale
plot (especially the portion before 2 us), which means that
the intensity is not decaying in time by a simple exponential
function. The disclosed Cu-Cy crystals exhibit intensive
luminescence centered at 633 nm when they are excited by
X-rays (FIG. 6).
FIG. 22 depicts the photoluminescence emission spec-
trum (360 nm) and X-ray luminescence of Cu-Cy together.
The XPSprofile of Cu-Cy crystals of the invention is shown
in FIG. 7. Without wishing to be limited by theory the
labeled peaks are assigned as follows: peak A Cu(3p), peak
B Cu@s), peak C S(2p), peak D Cl(2p), peak E S(2p), peak
F Cld1s), peak G Ag(3d), peak H N(1s), peak I O(1s), peak
J Ag(3p3/2), peak K Ag(3p1/2), peak L Cu(Auger), peak M
Ag(3s), peak N Cu(2p3/2), peak O Cu(2p1/2) and peak P
O(Auger). Ag signals are seen because Ag film is used for
coating on the surface of a small silicon wafer in XPS
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sample preparation. O signals displayed in the XPS are due
to absorbance by O on the sample surface.
METHODS
Photodynamic Therapy
Disclosed herein are methods for using the disclosed
complex as a treatment for cancer. The methods and uses
relate to the ability of the disclosed Cu-Cy complex to serve
as an effective agent for photodynamic therapy. Photody-
namic therapy (PDT)has attracted ever-growing attention as
a promising modality in the treatment of cancer. However,
due to the poor tissue penetration by light, PDT has rarely
been applied for deep-seated tumors. This problem can be
solved if photosensitizers are activated by X-rays, which are
able to penetrate deeply into tissues. Previous attempts at
using X-rays to activate photosensitizers were not very
successful, since the traditional PDT photosensitizers cannot
efficiently be activated with X-rays. Photodynamic therapy
(PDT) and photothermal therapy (PTT) are two major
cancer treatments by using electromagnetic radiation. Cells
are killed by singlet oxygen generated in PDT while high
temperature is utilized in PTT.
Accordingly, the disclosed Cu-Cy complex can be used to
treat a variety of mammalian tumors. As used herein, the
term “treating”refers to: (1) preventing a disease, disorder or
condition from occurring in a mammal, animal or human
that may be predisposed to the disease, disorder and/or
condition but has not yet been diagnosed as having it; (11)
inhibiting the disease, disorder or condition,i.e., arresting its
development; and/or (iii) relieving the disease, disorder or
condition, i.e., causing regression of the disease, disorder
and/or condition. For example, with respect to cancer,
treatment may be measured quantitatively or qualitatively to
determine the presence/absence of the disease, or its pro-
gression or regression using, for example, reduction in
tumorsize, a reduction in the rate of metastasis, and/or a
slowing of tumor growth, and/or no worsening in disease
over a specified period of time or other symptomsassociated
with the disease or clinical indications associated with the
pathology of the cancer.
As mentioned above, the disclosed Cu-Cy complex and
methods can be used in imaging oftarget tissue or tumors,
to treat any number of cancers or tumors or both. The
disclosed Cu-Cy complex is particularly suited for the
imaging and/or treatment of deep tissue tumors, such breast
cancer, ovarian cancer, brain cancer, lung cancer, hepatic
cancers, and the like. Types of mammalian tumors that can
be treated using the disclosed Cu-Cy complex and methods
include, but are not limited to all solid tumors, cutaneous
tumors, melanoma, malignant melanoma,renal cell carci-
noma, colorectal carcinoma, colon cancer, hepatic metasta-
ses of advanced colorectal carcinoma, lymphomas (includ-
ing glandular lymphoma), malignant lymphoma, Kaposi’s
sarcoma, prostate cancer, kidney cancer, ovarian cancer,
lung cancer, head and neck cancer, pancreatic cancer, mes-
enteric cancer, gastric cancer, rectal cancer, stomach cancer,
bladder cancer, leukemia (including hairy cell leukemia and
chronic myelogenous leukemia), breast cancer, solid breast
tumor growth, non-melanoma skin cancer (including
squamouscell carcinoma and basal cell carcinoma), heman-
gioma multiple myeloma, and glioma. In one embodiment,
the cancer is brain, breast, lung, pancreatic, hepatic, colon,
melanoma, ovarian cancer, or metastases thereof. In addi-
tion, embodiments for the invention can be adapted for
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non-solid tumors, including leukemias or lymphomas, via
whole-body PDT therapy using the disclosed Cu-Cy com-
plex.
In one aspect, the methods include administering systemi-
cally or locally the disclosed Cu-Cy complex. Any suitable
route of administration may be used, including, for example,
topical, intravenous, oral, subcutaneous, local (e.g. in the
eye) or by use ofan implant. Advantageously, the small size,
colloidal stability, non-agglomeration properties, and
enhancedhalf-life of the disclosed Cu-Cy complex makesit
especially suitable for intravenous administration. Addi-
tional routes of administration are subcutaneous, intramus-
cular, or intraperitoneal injections in conventional or con-
venient forms. For topical administration, the disclosed
Cu-Cy complex can be in standard topical formulations and
compositions including lotions, suspensions or pastes. For
example, ICG encapsulation of the disclosed Cu-Cy com-
plex can be administered by various means, but preferably
by intravenous injection.
The dose of photosensitizer-encapsulated nanoparticles
may be optimizedbythe skilled person depending on factors
such as, but not limited to, the photosensitizer chosen, the
nature ofthe therapeutic protocol, the individual subject, and
the judgmentof the skilled practitioner. Preferred amounts
of photosensitizer-encapsulated nanoparticles are those
whichare clinically or therapeutically effective in the treat-
ment method being used. Such amounts are referred herein
as “effective amounts”.
Depending on the needs of the subject and the constraints
of the treatment method being used, smaller or larger doses
of disclosed Cu-Cy complex may be needed. The doses may
be a single administration or include multiple dosages over
time.
The disclosed Cu-Cy complex is administered to the
subject and the tumoror tissue in the subject is exposed for
a sufficient amount of time to a photo-activating amount of
light at a wavelength that activates the disclosed Cu-Cy
complex sufficient to obtain the desired response. In some
cases, the desired response is the ability to bioimage or
detect the target tissue or tumor, or to perform photodynamic
therapy using the methods and disclosed Cu-Cy complex for
a sufficient period oftime effective to inhibit or reduce tumor
growth or tumor size. The desired response may be com-
pared to a control if desired.
In general, disclosed are methods for treating tumors or
imaging targeted tissue in a subject, comprising:
a) administering to a subject an effective amount of a
compound having the formula:
Cu3Cl(SR),
wherein R is —CH,CH,NH, (the disclosed Cu-Cy
complex); and
b) exposing the tumor or targeted tissue to a photo-
activating amount of electromagnetic radiation at a
wavelength that actives the compound.
In one aspect the electromagnetic radiation can be from a
source of X-rays or from a source ofultraviolet light. The
tumorortargeted tissue 1s typically irradiated for a sufficient
amountoftime to obtain a desired response. The formulator,
however, can use any source of radiation, for example, a
radiation source chosen from an X-ray source, a gamma-ray
source, a beta-ray source, a source of proton emission, a
source of electron emission, or a source of neutron emission
The desired response is determined by the formulator or
user.
US 9,593,131 B2
11
In one aspect, disclosed is a method for treating cancer,
comprising:
a) contacting a cancerouscell with an effective amount of
the disclosed Cu-Cy complex; and
b) irradiating the Cu-Cy complex.
In another aspect, the disclosed method comprises:
a) contacting a tumor with an effective amount of the
disclosed Cu-Cy complex; and
b) irradiating the Cu-Cy with a source of X-rays to
produce single oxygen.
The treatment can be performed in any manner chosen by
the formulator. For example, the complex can be injected via
syringe or any other suitable delivery meanstothesite of the
tumor. The source of radiation can be applied by any
convenient means compatible with the location of the tumor.
The method can be conducted during surgery, for example,
with or without excising the tumor. In oneiteration of this
aspect, the complex can be administered topically to cancers
of the skin.
Another aspect of the disclosure relates to a method for
treating cancer in a subject, comprising:
a) co-administering to the cancer cells compound having
the formula:
CusCl(SR)>
wherein R is —CH,CH,NH,and a radio isotope; and
b) optionally irradiating the cancer cells with a source of
electromagnetic radiation.
In one embodiment of the disclosure the metastable
isotope of technetium, Tc-99m, is co-administered with the
Cu-Cy. The admixture ofCu-Cy andthe radio isotope can be
further irradiated. The further irradiation can be accom-
plished using a source of radiation is chosen from an X-ray
source, a gamma-ray source, a beta-ray source, a source of
proton emission, a source of electron emission, or a source
of neutron emission.
Anotheraspect relates to the use of the disclosed Cu-Cy
complex for making a medicament for the treatment of
cancer. In still another aspect, disclosed herein is the use of
the disclosed Cu-Cy complex as a treatment for cancer.
Without wishing to be limited by theory, particles of the
disclosed Cu-Cy complex can beefficiently activated by
X-rays to produce singlet oxygen, i.e., as a means from
providing photodynamic therapy (PDT). PDT uses several
different mechanisms to destroy tumors. A photosensitizer
can target tumorcells directly, inducing necrosis or apop-
tosis. Alternatively, by the targeting of tumor vasculature,
the tumorcan be starved of oxygen-carrying blood.
Asit relates to the use ofthe disclosed Cu-Cy complex for
cancer treatment, the Cu-Cy photosensitizers have several
unique characteristics:
(i) Cu-Cy particles themselves are photosensitizers that
can be activated directly by X-rays. As such, there is no need
to use other sensitizing agents or nanoparticles;
(ii) Cu-Cy particles emit luminescence, permitting their
use as a diagnostic imaging agent;
(iii) Cu-Cy particles can be fabricated at the nanoscale to
increase water solubility and cellular uptake;
(iv) Cu-Cy complex in the form of nanoparticles can also
be tagged with functional groups for targeted delivery;
(v) Cu-Cy complex have low cytotoxicity; and
(vi) Cu-Cy complex are easy to synthesize and inexpen-
sive.
The disclosed Cu-Cyparticles can be used for deep-seated
cancers, thereby surpassing the limits of traditional PDT
which is presently restricted to treatment of superficial
tumors.
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The X-ray induced Cu-Cy photosensitizer provides a
novel concept for PDT. In addition, Cu-Cyparticles can be
used for cell imaging during cancer treatment because these
particles have strong photoluminescence and X-ray excited
luminescence. Overall, the Cu-Cy photosensitizers of the
invention will have a significant impact on the treatment of
deep cancer.
The toxicity of Cu-Cy crystals in MCF-7 cells was
evaluated using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide) assay. 2 mg of the Cu-Cy
crystals were well ground and sonicated before being dis-
solved in 1 mL of DI water (control) for the measurement.
As seen in FIG. 9, the cellular viability gradually decreased
from about 95% to about 70% when the Cu-Cy concentra-
tion was increased from 0.1 ug/ml to 200 ug/ml.
FIG. 10A is the bright-field image of MCR-7 breast
cancer cells after incubation with the disclosed Cu-Cy
complex. In order to review the cell uptake of the Cu-Cy
crystals, we incubated the crystals with human breast cancer
(MCF-7) cells for 24 hours. Cells were then stained with
4',6-Diamidino-2-phenylindole (DAPI) and their nuclei
were clearly seen when using excitation of 405 nm and
filtering red wavelengths out (FIG. 10B). The red emission
shown in FIG. 10C results from Cu-Cy crystals excited at
360 nm. FIG. 10D is a photo combination of FIGS. 10B and
10C.
Human Hepatocellular Liver Cells
FIGS. 11A-11D depict the effectiveness of the Cu-Cy
material as causing cell death when irradiated with UV light
or X-ray. For example, in FIGS. 11A-11D,the fluorescence
images ofhuman hepatocellular liver cells were taken before
and after the UV light exposure (350 nm,for 2 minutes, from
an OLYMPUS1X71 microscope). Calcein and Ethidium
homodimer 1 (EthD-1) were usedas the stains showingcell
alive (green) and death (red) respectively.
Each of the images was taken right after the staining
without further liver cell incubation. As seen in FIGS.
11A-11B, UV light aloneis ineffective in causing cell death.
The presence of Cu-Cy crystals alone (FIG. 11C) does not
result in significant cell death; however, when irradiated
with a UV source, there is significant cell death as demon-
strated in FIG. 11D.
MCE-7 Breast Cancer Cells
Photo-induced toxicity was then applied to cancercells.
FIGS. 12A-12D displays a similar fluorescence imaging
study but using breast cancer (MCF-7) cells. As in the case
of the cancer cells, significant cellular death occurs when
cells exposed to the disclosed Cu-Cy complexare irradiated
with a source of UV light.
Asstated herein above, the disclosed Cu-Cy compound
also absorbs X-rays and emits a luminescent spectrum. FIG.
13A-13D depicts the MCF-7 cell viabilities by fluorescence
images with and without Cu-Cy crystals and with and
without X-ray irradiation. As with UV radiation, X-ray
irradiation of cells incubated with the disclosed Cu-Cy
complex is also an effective method for causing cell death.
FIGS. 14A-D depict fluorescence images of MCF-7 cells
before and after 1 Gy X-ray exposure by an OLYMPUS
IX71 microscope. Calcein and ethidtumhomodimer 1
(EthD-1) were usedas the stains showing cells alive (green)
and dead (red) respectively. Each of the images was taken
immediately after staining, without further cell incubation.
Asindicated, applied X-ray dose alone does notkill the cells
without Cu-Cyparticles (FIG. 13A and FIG. 13B). There is
little cell death in the presence of Cu-Cy particles alone
(FIG. 13C). When the Cu-Cy and X-ray treatment are
coupled, significant cell destruction results (FIG. 13D).
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Human Prostate Cancer (PC-3) Cells
FIG. 14A-14D show comparable results for humanpros-
tate cancer cells incubated with the disclosed Cu-Cy com-
pound andirradiated with an X-ray source versus control. As
such, the combination of the disclosed Cu-Cy material and
a source of radiation provides an effective method for
inducing cell death.
The cellular toxicity in PC-3 cells at various concentra-
tions of Cu-Cy (Si), Cu-Cy treated by UV light (S2), and
Cu-Cytreated by X-ray irradiation (S3) is depicted in FIG.
15. Reading FIG.15 from left to right: Control sample, PC-3
cells incubated with 0.2 mg/mL Si, PC-3 cells incubated
with 0.02 mg/mL Si, PC-3 cells incubated with 0.2 mg/mL
$2, PC-3 cells incubated with 0.02 mg/mL 82, PC-3 cells
incubated with 0.2 mg/mL 83, and PC-3 cells incubated with
0.02 mg/mL S83.
Singlet Oxygen
To evaluate whether Cu-Cy particles produce singlet
oxygen as a method for treating cancer via irradiation by
X-rays the p-nitrosodimethylaniline (RNO)-imidazole(ID)
method (Kralji¢ et al., “A New Method for the Detection of
Singlet Oxygen in AqueousSolutions,” Photochemistry and
Photobiology, Vol. 28: Issue 4-5, 577-581 (1978)) was used
to detect whether singlet oxygen was produce using various
X-ray doses. RNO is a water-soluble molecule with absorp-
tion that can be quenchedirreversibly by singlet oxygen in
the presence of ID. FIG. 18A depicts the decrease in RNO
absorbance over a range of X-Ray doses for zine oxide,
protoporphyrin IX (PPIX) and the disclosed Cu-Cy complex
versus control. The amountof singlet oxygen formation by
ZnO as measured by the loss in RNO absorption was
relatively low as compared with control. PPIX exhibited a
modest increase over ZnO. The disclosed Cu-Cy complex
exhibited an almostlinear relationship of increasing singlet
oxygen formation and wassix-times greater than PPIX at 8
Gy. FIG. 18B depicts the same experiment omitting ZnO,
but using ultra violet light as the radiation source.
Singlet Oxygen Measurement.
p-nitrosodimethylaniline(RNO) (0.225 mg) and imidazo-
le(ID) (16.34 mg) were added to 30 mL DI water, which was
air saturated by sufficient air bobbling. The sample solution
was prepared by adding 1 mg of testing sample (Cu-Cy,
PPIX, or ZnO) into 3 mL above RNO-ID solution. Then, the
RNO-IDsolution and sample solutions were exposed under
different X-ray doses (0 to 8 Gy) using a Faxitron RX-650
cabinet X-ray system (Faxitron X-ray LLC, USA). Mean-
while, the intensity of RNO absorption peak at 440 nm of
different solutions was monitored by a Shimadzu UV-vis
spectrophotometer.
Subcutaneous Tumor Model
A suspension of 10x10°MCF-7 cancer cell lines was
injected subcutaneously into flanks on both shoulder and leg
area of nude mice. Mice were monitored on a daily basis for
the growth of tumors (FIG. 24). When the tumors reached
about 3-4 mm in diameter, mice were divided randomly into
two groups: one group received X-ray irradiation and the
other group did not. Saline (10 uL, as control, left shoulder)
and Cu-Cywith concentration about 0.8 mg/mL (10 pL-right
shoulder, 15 wL-left leg and 20 pL-right leg) were injected
intra-tumorally. At one minute post-injection, mice were
anesthetized with 2% (v/v) isofluorane, and tumors were
irradiated with an X-ray dose of 5 Gy. Without X-ray
treatment(top row), the tumors grew as time progressed, and
there was no apparentsize difference among Cu-Cy dosages
of 10, 15, and 20 wl. Meanwhile, the tumors with no Cu-Cy
(saline only) treatment were larger than the tumors with
Cu-Cy treatment. This observation suggests that the Cu-Cy
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exhibits slight toxicity in vivo, but does not significantly
reduce tumor size or growth, regardless of the applied
Cu-Cy dose. However, with X-ray radiation (bottom row),
the tumor growth was greatly reduced for 15 and 20 uL it
Cu-Cy dosages. The animals were sacrificed via CO, inha-
lation and cervical decapitation on the day 13 of tumor
growth. The tumors were surgically dissected and are shown
in FIG. 25. Absent X-ray radiation (top row), the tumors
without Cu-Cy treatment grew to a somewhatlarger volume
than those treated by Cu-Cy, which indicates the minor
toxicity from the Cu-Cy particles themselves. The similar
size of tumors treated by 10, 15, or 20 uL of Cu-Cy reveals
that high Cu-Cy dosage does not affect tumor growth.
However, whenactivated by X-ray, the higher Cu-Cy dosage
greatly reduced the tumor volume (bottom row). X-ray
radiation in the absence of Cu-Cydid not contribute to any
tumorsize reduction. This is seen by comparing the two
tumors treated with saline with and without X-ray radiation.
For the treatment with 20 uL of Cu-Cy particles at 5 Gy
dose, the tumor size is reduced to about 3 mm in diameter
while the untreated tumor size is about 10 mm in diameter.
These observations and conclusions are consistent with the
work shown in FIG. 24. The preliminary results show that
Cu-Cyis a promising photosensitizer for cancer treatment.
Cell Culture and Cell Uptake of Cu-Cy Particles
The MCF-7 cell lines were purchased from ATCC
(American Type Culture Collection) and grown in chamber
slides in RPMI 1640 and Ham’s F12K medium, respec-
tively, supplemented with 100 units/mL aqueous penicillin
G, 100 pg/mL streptomycin, and 10% fetal bovine serum at
concentrations that allowed 70% confluence in 24 h. On the
day of experimentation, cells were washed with pre-warmed
PBS and incubated with pre-warmed phenol-red-reduced
OptiMEM media for 30 min. before the addition of 50 pg of
Cu-Cyparticles. Cells were incubated with Cu-Cy for 24
hours at 37° C., then washed with PBS three times, fixed
with 4% paraformaldehyde, counterstained with 4',6-diami-
dino-2-phenylindole and Alexa-Flour Phalloidin, mounted,
and visualized by a fluorescence microscope.
Cytotoxicity Test
Cytotoxicity was evaluated using the MITT assay.
Approximately 2,000 cells/well MCF-7 cells were seeded
into 96-well plates and allowed to grow for 48 hours in an
incubator (Sanyo, Japan, 5% CO2, 37° C., humidified atmo-
sphere). On the day of the experiment, after removing the
culture medium, different volumes of media containing
Cu-Cy particles were added to their respective wells and
cytotoxicity was evaluated after 24 h of cell incubation
In Vitro Cell Destruction Using Fluorescence Imaging
MCE-7 cells were seeded into two 6-well plates (A and B)
at ~5,000 cells/well and incubated for 48 h at 37° C. ina
humidified atmosphere of 5% v/v CO, at dark. On the day
of the experiment, the culture medium was removed and 5
mL medium containing 0 and 40 ug/ml Cu-Cyparticles were
addedto different wells. After other 24 hours cell culture, the
cells in plate A were irradiated with 2 Gy X-ray andcells in
plate B were not. Then, cells were incubated with 500 uL of
dye mixture (Calcein and EthD-1) for 30 min under standard
cell culture conditions in the dark. Unincorporated dyes
were removed by washing, following which culture wells
were replenished with media. The cells were viewed under
an OLYMPUSIX71 fluorescence microscope.
Radiation Detection
Further disclosed herein is the use of the disclosed Cu-Cy
complex for the detection of radiation. The radiation can be
from any source, inter alia, alfa, gamma, beta, neutron,
cosmic rays or any high energy particles. In addition, the
US 9,593,131 B2
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disclosed complex can be used for medical imaging such as
an X-ray intensifier, detectors for computed tomography
(CT), position-emission tomography (PET) and computed
radiography (CR). Furtherstill, they can be used for cath-
odoluminescence induced by electron beams for monitor
screens as as TVs, computers, or any displays related to
cathodolumienscence or electron beams. The radiation
detection by detecting singlet oxygen producedby radiation
is particularly useful for radiation detection in solutions such
as water. In addition, the material and method can be used 10
for biological sensing and detection, as well as for light
detection and sensing.
In one aspect the present disclosure relates to a method for
the detection of radiation, comprising contacting the dis-
closed Cu-Cy complex with a source of electromagnetic
radiation.
In a further aspect the present disclosure relates to a
method for detecting radiation, comprising:
a) exposing the disclosed Cu-Cy compoundto a source of
radiation; and
b) measuring the emission spectrum produced.
In a still further aspect the present disclosure relates to a
methodfor detecting a source ofradiation or for determining
if a source of radiation is present, comprising:
a) coating the surface of a substrate that is unaffected by
radiation with the disclosed Cu-Cy compound;
b) exposing the surface comprising the disclosed Cu-Cy
compoundto a site or object suspected of producing a
source of radiation; and
c) determining if the surface emits photoluminescence.
Photoluminescence
Also disclosed herein is a method of producing photolu-
minescentlighting, comprising irradiating a compound hav-
ing the formula:
CusCl(SR)>
wherein R is —CH,CH,NH,; with a source of electromag-
netic radiation.
Other advantages which are obvious and whichare inher-
ent to the invention will be evident to one skilled in the art.
It will be understood that certain features and sub-combi-
nationsare ofutility and may be employed withoutreference
to other features and sub-combinations. This is contem-
plated by and is within the scope of the claims. Since many
possible embodiments may be madeofthe invention without
departing from the scope thereof, it is to be understood that
all matter herein set forth or shown in the accompanying
drawings is to be interpreted as illustrative and not in a
limiting sense.
Whatis claimed is:
1. A compound having the formula:
Cu;Cl(SR),
wherein R is —CH,CH,NH).
2. The compound according to claim 1, wherein the
compound crystallizes in the monoclinic space group C2/c
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and cell parameters are a=7.5510(4) A, b=16.9848(7) A,
c=7.8364(4) A, B=104.798(3)°.
3. A methodfor treating cancer in a subject, comprising:
a) contacting the cancer cells an effective amount of a
5 compound having the formula:
CusCl(SR)>
wherein R is —CH,CH,NH,; and
b) irradiating the cells with a source of electromagnetic
radiation wherein the canceris breast canceror prostate
cancer.
4. The method according to claim 3, wherein the source
of radiation is chosen from an X-ray source, a gamma-ray
source, a beta-ray source, a source of proton emission, a
source of electron emission, or a source ofneutron emission.
5. The method according to claim 3, wherein the source
of electromagnetic radiation is a source of ultraviolet light.
6. The method according to claim 3, wherein source of
radiation is the radio isotope technecium-99m.
7. The method according to claim 3, wherein the source
of electromagnetic radiation is an X-ray source.
8. A method for producing singlet oxygen in a cell,
comprising contacting the cell with a compoundhaving the
formula:25
Cu3Cl(SR)p
wherein R is —CH,CH,NH,;andirradiating the cell with
a source of electromagnetic radiation
wherein the cell is a breast cancer or prostate cancercell.
9. The method according to claim 8, wherein the source
of radiation is chosen from an X-ray source, a gamma-ray
source, a beta-ray source, a source of proton emission, a
source of electron emission, or a source ofneutron emission.
10. The method according to claim 8, wherein the source
of electromagnetic radiation is a source of ultraviolet light.
11. The method according to claim 8, wherein source of
radiation is the radio isotope technecium-99m.
12. The method according to claim 8, wherein the source
of electromagnetic radiation is an X-ray source.
13. A method of producing photoluminescent lighting,
comprising irradiating a compound having the formula:
30
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CusCl(SR)>
wherein R is —CH,CH,NH,;
with a source of electromagnetic radiation.
14. The method according to claim 13, wherein the source
of radiation is chosen from an X-ray source, a gamma-ray
source, a beta-ray source, a source of proton emission, a
source of electron emission, or a source ofneutron emission.
15. The method according to claim 13, wherein the source
of electromagnetic radiation is a source of ultraviolet light.
16. The method according to claim 13, wherein the source
of electromagnetic radiation is an X-ray source.
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